Concord Biotech Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Concord Biotech Ltd trades at ₹1,343, in a downtrend and 46 weeks into that stage. That is +2.6% against its own 200-day average. It sits at 44% of a 52-week range of ₹1,015 to ₹1,768. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 10 straight weeks.

Today the stock is in a downtrend — week 46 of stage 4, confirmed. At ₹1,343 it trades +2.6% versus its 200-day average and sits at 44% of its 52-week range (₹1,015–₹1,768).

Against the market, two honest reads. Cumulative: over the last 2.9 years the stock moved +42% while the NIFTY 500 moved +38% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 69th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Concord Biotech Ltd trades at 54.8× P/E, mid-range by its own standards (69th percentile). Its long-run median P/E is 51.7×, measured across 2.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 54.8× is mid-range by its own standards (69th percentile), against a long-run median of 51.7× measured over 2.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −29.8% against a −29.1% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +12.5%/yr price move, ~+0.1%/yr came from earnings growth and ~+12.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Concord Biotech Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −30.4% latest against +28.9% at its 12-quarter best), ROCE slipping at 17.6%. The read is built from 12 quarters across 4 curves, on full evidence.

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

41.3/100 — rank 15 of 24 in Pharma - API & CRAMS · 90% evidence confidence

Concord Biotech Ltd scores 41.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 15. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 6.5 + 20 + 9.3 + 5.5 = 41.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Concord Biotech Ltd reported ₹326 Cr of revenue in the Mar 26 quarter, −24.2% year on year. Over 6 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹1,055 Cr. The last four reported quarters add to ₹1,055 Cr.

Concord Biotech Ltd reported ₹326 Cr of revenue in the Mar 26 quarter, −24.2% year on year. Over 6 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹1,055 Cr. The last four reported quarters add to ₹1,055 Cr.

FY26 revenue came in at ₹1,055 Cr (−12.1% on the year), capping 6 years at 12.8% compound. The latest quarter (Mar 26) printed ₹326 Cr, −24.2% year on year.

Pace check: the last four quarters averaged −9.0% growth against the decade's 12.8% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −12.1% over the last 4 quarters against +1.9%/yr over the last 8 — rolling over; TTM profit −30.4% vs −8.3%/yr — rolling over.

→ Revenue slipped — did margins hold as it scaled? Next: 36.0% this quarter (−8.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Concord Biotech Ltd's operating margin is 36.0% in the Mar 26 quarter, −8.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 35.0% to 53.0%. The current quarter sits inside that band.

Concord Biotech Ltd's operating margin is 36.0% in the Mar 26 quarter, −8.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 35.0% to 53.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 36.0%, −8.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 35.0%–53.0%.

🚨 Why the margin moved: operating margin went −7.6 pp year on year while gross margin went +1.3 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit −37.1% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Concord Biotech Ltd earned ₹88.0 Cr of net profit in the Mar 26 quarter, −37.1% year on year. Full-year FY26 profit was ₹259 Cr. The 6-year compound rate is 7.4%. That is 27.0% of the quarter's revenue. The same quarter a year earlier earned ₹140 Cr.

Concord Biotech Ltd earned ₹88.0 Cr of net profit in the Mar 26 quarter, −37.1% year on year. Full-year FY26 profit was ₹259 Cr. The 6-year compound rate is 7.4%. That is 27.0% of the quarter's revenue. The same quarter a year earlier earned ₹140 Cr.

Mar 26 profit was ₹88.0 Cr, −37.1% year on year. On the full year, FY26 printed ₹259 Cr (−30.4%), and the 6-year compound rate is 7.4%.

🚨 Why profit moved: revenue contributed −24.2% and the margin −8.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −28.5% vs revenue −9.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 83% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 83% of Concord Biotech Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹267 Cr of operating cash against ₹259 Cr of profit. After ₹96.0 Cr of capital spending, ₹171 Cr was left as free cash.

FY26: operating cash of ₹267 Cr against reported profit of ₹259 Cr, leaving free cash of ₹171 Cr after ₹96.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 83% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 83%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 1.6× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹284 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Concord Biotech Ltd's cash conversion cycle runs 493 days in FY26, up from 456 days in FY21. Capital spending ran ₹284 Cr over the last 3 years. At FY26 sales of ₹1,055 Cr each day of that cycle holds about ₹2.9 Cr, so roughly ₹1,425 Cr sits inside the business at any moment.

FY26: debtors at 159 days, inventory at 485 days — roughly 16.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 493 days, looser than FY21's 456.

The full loop: cash goes out to suppliers and production on day 0; stock waits 485 days to sell; customers pay about 159 days after that; and suppliers themselves are paid at 151 days — netting out to the 493-day cycle.

In money terms: at FY26 sales of ₹1,055 Cr, each day of the cycle holds about ₹2.9 Cr — so the 493-day loop keeps roughly ₹1,425 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹284 Cr over the last 3 fiscal years against ₹182 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹79.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 17% and the ROIC − WACC spread is +2.8 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Concord Biotech Ltd earns a ROCE of 17% in FY26. Return on invested capital clears the cost of that capital by +2.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 24.5% net margin on 0.47× asset turns.

FY26 ROCE is 17%.

Why the return is what it is — the wiring (FY26): 24.5% net margin × 0.47× asset turns × 1.11× balance-sheet leverage ≈ 12.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 14.8% − 12.0% = a +2.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Concord Biotech Ltd carries total debt of ₹2.0 Cr against shareholder equity of ₹2,015 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.02 in FY23 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹2.0 Cr against shareholder equity of ₹2,015 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.02 (FY23) to 0.00 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 1.0 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions cut 1.0 points of Concord Biotech Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 9.4% of the company. Foreign institutions moved +0.4 points over the same window, to 7.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: −1.0 points over 8 quarters to 9.4%; Foreign institutions: +0.4 points over 8 quarters to 7.5%; Promoters: +0.0 points over 8 quarters to 44.1%.

🚨 Why the register moved: domestic institutions drove it (−1.0 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Concord Biotech Ltd: the Z-score reads 46.22. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 46.22 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 46.22.

Frequently asked questions